Madrigal Pharmaceuticals (MDGL) Profit After Tax (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Profit After Tax for 17 consecutive years, with -$57.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Profit After Tax fell 37.03% year-over-year to -$57.9 million; the TTM figure through Jun 2026 stood at -$325.1 million (down 15.33% YoY), while the FY2025 annual figure was -$288.3 million, up 38.12% from the prior year.
• Profit After Tax advanced to -$57.9 million in Q2 2026 per MDGL's latest filing, from -$94.4 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$42.3 million in Q2 2025 and bottomed at -$152.0 million in Q2 2024.
• Historically, Profit After Tax has averaged -$87.5 million across 5 years, with a median of -$83.5 million in 2022.
• Annual changes were most pronounced in 2024 — Profit After Tax sank 91.87% — and 2025, when it soared 72.18%.
• Madrigal Pharmaceuticals' Profit After Tax stood at -$85.9 million in 2022, then sank by 30.6% to -$112.2 million in 2023, then soared by 47.04% to -$59.4 million in 2024, then climbed by 1.39% to -$58.6 million in 2025, then increased by 1.11% to -$57.9 million in 2026.
• Business Quant data shows MDGL's Profit After Tax at -$57.9 million in Q2 2026, -$94.4 million in Q1 2026, and -$58.6 million in Q4 2025.